Xf Steven Zheng

List of Publications by Citations

42 papers	2,275 citations	23 h-index	44 g-index
44 ext. papers	2,646 ext. citations	8.9 avg, IF	5.09 L-index

#	Paper	IF	Citations
42	Targeting mammalian target of rapamycin (mTOR) for health and diseases. *Drug Discovery Today*, **2007**, 12, 112-24	8.8	320
41	Nutrient regulates Tor1 nuclear localization and association with rDNA promoter. *Nature*, **2006**, 442, 1058-61	50.4	242
40	Rab1A is an mTORC1 activator and a colorectal oncogene. *Cancer Cell*, **2014**, 26, 754-69	24.3	171
39	Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. *Drug Discovery Today*, **2011**, 16, 325-31	8.8	153
38	Expanding roles of superoxide dismutases in cell regulation and cancer. *Drug Discovery Today*, **2016**, 21, 143-149	8.8	128
37	FKBP12-rapamycin-associated protein or mammalian target of rapamycin (FRAP/mTOR) localization in the endoplasmic reticulum and the Golgi apparatus. *Journal of Biological Chemistry*, **2004**, 279, 772-8	5.4	127
36	Mechanisms of regulation of RNA polymerase III-dependent transcription by TORC1. *EMBO Journal*, **2009**, 28, 2220-30	13	112
35	Convergence of TOR-nitrogen and Snf1-glucose signaling pathways onto Gln3. *Molecular and Cellular Biology*, **2002**, 22, 1246-52	4.8	96
34	Endoplasmic reticulum and Golgi localization sequences for mammalian target of rapamycin. *Molecular Biology of the Cell*, **2007**, 18, 1073-82	3.5	79
33	Toward rapamycin analog (rapalog)-based precision cancer therapy. *Acta Pharmacologica Sinica*, **2015**, 36, 1163-9	8	72
32	SOD1 Phosphorylation by mTORC1 Couples Nutrient Sensing and Redox Regulation. *Molecular Cell*, **2018**, 70, 502-515.e8	17.6	63
31	Recent clinical trials of mTOR-targeted cancer therapies. *Reviews on Recent Clinical Trials*, **2011**, 6, 24-35	1.2	63
30	mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. *Cell Cycle*, **2012**, 11, 594-603	4.7	58
29	Nutrient starvation promotes condensin loading to maintain rDNA stability. *EMBO Journal*, **2007**, 26, 448-58	13	57
28	Emerging Role of MicroRNAs in mTOR Signaling. *Cellular and Molecular Life Sciences*, **2017**, 74, 2613-2625	10.3	56
27	Sch9 partially mediates TORC1 signaling to control ribosomal RNA synthesis. *Cell Cycle*, **2009**, 8, 4085-90	4.7	54
26	Aberrant amino acid signaling promotes growth and metastasis of hepatocellular carcinomas through Rab1A-dependent activation of mTORC1 by Rab1A. *Oncotarget*, **2015**, 6, 20813-28	3.3	48

25	MAF1 suppresses AKT-mTOR signaling and liver cancer through activation of PTEN transcription. *Hepatology*, **2016**, 63, 1928-42	11.2	48
24	Significance and mechanism of androgen receptor overexpression and androgen receptor/mechanistic target of rapamycin cross-talk in hepatocellular carcinoma. *Hepatology*, **2018**, 67, 2271-2286	11.2	46
23	SOX9 is targeted for proteasomal degradation by the E3 ligase FBW7 in response to DNA damage. *Nucleic Acids Research*, **2016**, 44, 8855-8869	20.1	28
22	Overexpression of Rab1B and MMP9 predicts poor survival and good response to chemotherapy in patients with colorectal cancer. *Aging*, **2017**, 9, 914-931	5.6	27
21	Reduced SOD2 expression is associated with mortality of hepatocellular carcinoma patients in a mutant p53-dependent manner. *Aging*, **2016**, 8, 1184-200	5.6	25
20	Maf1 regulation. *Nucleus*, **2010**, 1, 162-165	3.9	24
19	BMP2 promotes proliferation and invasion of nasopharyngeal carcinoma cells via mTORC1 pathway. *Aging*, **2017**, 9, 1326-1340	5.6	21
18	PP2AC Level Determines Differential Programming of p38-TSC-mTOR Signaling and Therapeutic Response to p38-Targeted Therapy in Colorectal Cancer. *EBioMedicine*, **2015**, 2, 1944-56	8.8	20
17	Maf1 regulation: a model of signal transduction inside the nucleus. *Nucleus*, **2010**, 1, 162-5	3.9	20
16	Beyond regulation of pol III: Role of MAF1 in growth, metabolism, aging and cancer. *Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms*, **2018**, 1861, 338-343	6	17
15	Identification of a Non-Gatekeeper Hot Spot for Drug-Resistant Mutations in mTOR Kinase. *Cell Reports*, **2015**, 11, 446-59	10.6	16
14	Opposing role of condensin and radiation-sensitive gene RAD52 in ribosomal DNA stability regulation. *Journal of Biological Chemistry*, **2009**, 284, 21908-21919	5.4	14
13	p53R2 overexpression in cervical cancer promotes AKT signaling and EMT, and is correlated with tumor progression, metastasis and poor prognosis. *Cell Cycle*, **2017**, 16, 1673-1682	4.7	13
12	SOD1 regulates ribosome biogenesis in KRAS mutant non-small cell lung cancer. *Nature Communications*, **2021**, 12, 2259	17.4	13
11	Sorafenib and Carfilzomib Synergistically Inhibit the Proliferation, Survival, and Metastasis of Hepatocellular Carcinoma. *Molecular Cancer Therapeutics*, **2018**, 17, 2610-2621	6.1	10
10	Amino acids-Rab1A-mTORC1 signaling controls whole-body glucose homeostasis. *Cell Reports*, **2021**, 34, 108830	10.6	6
9	Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma. *Drug Discovery Today*, **2021**, 26, 1539-1546	8.8	6
8	Exome sequencing reveals the genetic landscape and frequent inactivation of PCDHB3 in Chinese rectal cancers. *Journal of Pathology*, **2018**, 245, 222-234	9.4	5

7	Rab1 GTPases as oncogenes. *Aging*, **2015**, 7, 897-8	5.6	5
6	Yin and yang of 4E-BP1 in cancer. *Cell Cycle*, **2016**, 15, 1401-2	4.7	5
5	mTORC1 Promotes ARID1A Degradation and Oncogenic Chromatin Remodeling in Hepatocellular Carcinoma. *Cancer Research*, **2021**, 81, 5652-5665	10.1	4
4	A balancing act: mTOR integrates nutrient signals to regulate redox-dependent growth and survival through SOD1. *Molecular and Cellular Oncology*, **2018**, 5, e1488372	1.2	1
3	A balancing act: mTOR integrates nutrient signals to regulate redox-dependent growth and survival through SOD1. *Molecular and Cellular Oncology*, **2018**, 5, e1488372	1.2	1
2	mTOR regulates aerobic glycolysis through NEAT1 and nuclear paraspeckle-mediated mechanism in hepatocellular carcinoma.. *Theranostics*, **2022**, 12, 3518-3533	12.1	0
1	Amino acids control blood glucose levels through mTOR signaling. *European Journal of Cell Biology*, **2022**, 101, 151240	6.1	0